Elizabeth Kantor, PhD, MPH

Associate Attending Epidemiologist, Geoffrey Beene Junior Faculty Chair
Epidemiology & Biostatistics
Directory
Epidemiology
Biostatistics
Health Outcomes
MSK Computational Oncology Department & Staff
Administrative Resources
Career Opportunities
Educational Opportunities
Departmental Newsletter

Elizabeth Kantor, PhD, MPH

Associate Attending Epidemiologist, Geoffrey Beene Junior Faculty Chair
Share
Share
Elizabeth Kantor

Office Phone

646-608-9372

Email

[email protected]

Education

PhD, University of Washington; MPH, University of Michigan

Current Research Interests

Dr. Kantor’s research centers on understanding how modifiable exposures, such as drugs and supplements, relate to cancer risk and survival. She seeks to address these research interests through use of data from a variety of sources, including epidemiologic cohorts, nationally representative surveys, and integrated healthcare delivery systems. Before moving to Memorial Sloan Kettering, Dr. Kantor completed a post-doctoral research fellowship at the Harvard School of Public Health, a PhD in Epidemiology at the University of Washington, and an MPH at the University of Michigan. 

Publications

Selected peer-reviewed publications:

  1. Kantor ED*, Rehm CD*, Haas JS, Chan AT, Giovannucci EL. Trends in Prescription Drug Use among Adults in the United States from 1999-2012. JAMA. 2015 Nov 3;314(17):1818-31. doi: 10.1001/jama.2015.13766. PMID: 26529160; PMCID: PMC4752169.*Denotes shared first authorship 
  2. Kantor ED*, O’Connell K*, Du M, Mendelsohn RB, Liang PS, Braunstein LZ. Ranitidine Use and Cancer Risk: Results From UK Biobank. Gastroenterology. 2021 Apr;160(5):1856-1859.e5. doi: 10.1053/j.gastro.2020.12.037. Epub 2020 Dec 29. PMID: 33385434; PMCID: PMC8035224.*Denotes shared first authorship 
  3. Kantor ED*, Rehm CD*, Du M, White E, Giovannucci EL. Trends in dietary supplement use among US adults from 1999-2012. JAMA. 2016 Oct 11;316(14):1464-1474. doi: 10.1001/jama.2016.14403. PMID: 27727382; PMCID: PMC5540241.*Denotes shared first authorship 
  4. Lee DH, Cao C, Zong X, Zhang X, O’Connell K, Song M, Wu K, Du M, Cao Y*, Giovannucci EL*, Kantor ED.* Glucosamine and Chondroitin Supplements and Risk of Colorectal Adenoma and Serrated Polyp. Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2693-2701. doi: 10.1158/1055-9965.EPI-20- 0805. Epub 2020 Oct 14. PMID: 33055203; PMCID: PMC7710617. *Denotes shared senior authorship
  5. Kantor ED*, Udumyan R*, Giovannucci EL, Valdimarsdottir UA, Signorello LB, Montgomery S, Fall K. Blood Marker of Inflammation in Late Adolescence Linked with Premature Mortality. JAMA Pediatr. 2019 Nov 1;173(11):1095-1097. doi: 10.1001/jamapediatrics.2019.2835. PMID: 31479147; PMCID: PMC6724417. *Denotes shared first authorship 

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Elizabeth Kantor discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures